Efficacy comparison of paclitaxel liposome or gemcitabine combined with cisplatin for treatment of elderly patients with advanced lung squamous cell carcinoma
10.3760/cma.j.issn.1006-9801.2017.11.004
- VernacularTitle:紫杉醇脂质体或吉西他滨联合顺铂治疗老年人晚期肺鳞状细胞癌效果比较
- Author:
Haiyuan XU
1
;
Zhangyi JI
;
Yan XU
;
Yue TAN
;
Minbin CHEN
Author Information
1. 215300,江苏大学附属昆山市第一人民医院肿瘤科
- Keywords:
Lung neoplasms;
Carcinoma,squamous cell;
Aged;
Paclitaxel liposome;
Gemcitabine
- From:
Cancer Research and Clinic
2017;29(11):736-739
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the clinical effects and safety of paclitaxel liposome or gemcitabine combined with cisplatin in elderly patients with advanced lung squamous cell cancer. Methods A total of 52 elderly patients with advanced lung squamous cell cancer in Kunshan First People's Hospital from January 2012 to October 2016 who received paclitaxel liposome with cisplatin (n=24) or gemcitabine with cisplatin(n = 28) were analyzed retrospectively. The patients received at least 2 cycles of chemotherapy, 2-6 cycles in total. CT was rechecked every 2 cycles. The clinical effects and adverse reactions were evaluated by National Cancer Institute Response Evaluation Criteria in Solid Tumors (NCI RECIST) and NCI Common Terminology Criteria for Adverse Events (NCI CTCAE). Results The objective response rate (ORR) and the disease control rate(DCR)in paclitaxel liposome group and in gemcitabine group had a lot in common [ORR:29.2 %(7/24)vs.32.1 %(9/28),χ2=0.054,P =0.817;DCR:70.8 %(17/24)vs.71.4 %(20/28),χ2=0.002,P =0.962]. The median progression-free survival(PFS) time in gemcitabine group was longer than that in paclitaxel liposome group (5.7 months vs. 5.4 months, χ2= 0.466, P = 0.495). One-year survival rate in gemcitabine group (37.0 %) was higher than that in paclitaxel liposome group (34.8 %) and there was no statistically significant difference (χ 2= 0.027, P = 0.869). However, hematologic adverse reactions in paclitaxel liposome group were lower than those in gemcitabine group (P< 0.05). Conclusion The effect of paclitaxel liposomes combined with cisplatin for treatment of elderly patients with advanced lung squamous cell carcinoma is not inferior to gemcitabine combined with cisplatin, which has less adverse reactions and may be recommended as the first-line chemotherapy for the patients.
